Healthcare costs and outcomes of managing β‐thalassemia major over 50 years in the United Kingdom

Transfusion - Tập 56 Số 5 - Trang 1038-1045 - 2016
Diana Weidlich1, Panos Kefalas2, Julian F. Guest1,3
1CATALYST Health Economics Consultants, Northwood, Middlesex, UK
2Cell Therapy Catapult Limited, London, UK
3Faculty of Life Sciences and Medicine, King's College London, UK

Tóm tắt

BACKGROUNDThe objective was to estimate the incidence‐based costs of treating β‐thalassemia major (BTM) to the United Kingdom's National Health Service (NHS) over the first 50 years of a patient's life in terms of healthcare resource use and corresponding costs and the associated health outcomes.STUDY DESIGN AND METHODSThis was a modeling study based on information obtained from a systematic review of published literature and clinicians involved in managing BTM in the United Kingdom. A state transition model was constructed depicting the management of BTM over a period of 50 years. The model was used to estimate the incidence‐based health economic impact that BTM imposes on the NHS and patients' health status in terms of the number of quality‐adjusted life‐years (QALYs) over 50 years.RESULTSThe expected probability of survival at 50 years is 0.63. Of patients who survive, 33% are expected to be without any complication and the other 67% are expected to experience at least one complication. Patients' health status over this period was estimated to be a mean of 11.5 discounted QALYs per patient. Total healthcare expenditure attributable to managing BTM was estimated to be £483,454 ($720,201) at 2013/14 prices over 50 years. The cost of managing BTM could be potentially reduced by up to 37% if one in two patients had a bone marrow transplant, with an ensuing improvement in health‐related quality of life.CONCLUSIONThis analysis provides the best estimate available of NHS resource use and costs with which to inform policy and budgetary decisions pertaining to this rare disease.

Từ khóa


Tài liệu tham khảo

FosterM HollingsworthR DarbyshireP et al. National haemoglobinopathy registry report 2013/14. Manchester (UK): Medical Data Services and Solutions;2014.

Standards for the clinical care of children and adults with thalassaemia in the UK. London:UK Thalassaemia Society;2008.

10.1111/j.1537-2995.2007.01416.x

10.1046/j.1365-2257.1999.00262.x

Borgna‐Pignatti C, 2004, Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine, Haematologica, 89, 1187

10.1093/ejechocard/jeq190

10.1007/s00277-013-1692-6

ChiricoV RigoliL PirainoB et al. Endocrinopathies in beta‐thalassemia major: evidences from 10 years of follow‐up and evaluation of combined iron chelation therapy. Hormone Research in Paediatrics Conference: 9th Joint Meeting of Paediatric Endocrinology ESPE–PES–APEG–APPES–ASPAE–JSPE–SLEP. Milan Italy;2013. p.318.

10.1016/j.bcmd.2009.01.002

10.1111/j.1365-2141.2009.07609.x

10.1016/S0140-6736(00)02357-6

10.1186/1532-429X-10-42

Telfer P, 2006, Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980‐2004, Haematologica, 91, 1187

10.1002/ajh.21398

10.1111/trf.12348

10.4999/uhod.12005

10.1177/0272989X11401031

Department of Health. NHS Reference Costs 2013 to 2014 [Internet]. London: NHS;2014[cited 2015 Jan 30]. Available from:https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014

10.1007/s12325-008-0085-z

Beta‐thalassemia [Internet]. London:NHS UK Genetic Testing Network;2015[cited 2015 Feb 3]. Available from:http://ukgtn.nhs.uk/find-a-test/search-by-disorder-gene/test-service/beta-thalassemia-543/#c3594

British National Formulary [Internet]. London: MedicinesComplete;2015[cited 2015 Jan 29]. Available from:www.medicinescomplete.com/about/

10.1046/j.1365-3148.2003.00443.x

10.1007/s40273-013-0076-z

Provider to provider services 2013‐2014 tariff. London:University College London Hospitals NHS Foundation Trust;2013.

Economic modelling for vascular checks [Internet]. London:Department of Health;2008[cited 2015 Feb 4]. Available from:http://www.healthcheck.nhs.uk/document.php?o=225.

Price list 2014‐2015. London:Homerton University Hospital;2014.

Drug tariff [Internet]. London:NHS Prescription Services;2015[cited 2015 Jan 29]. Available from:http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx.

KanavosP van denAardwegS SchurerW.Diabetes expenditure burden of disease and management in 5 EU countries [Internet]. London: LSE Health London School of Business;2012[cited 2015 Feb 5]. Available from:http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf.

10.1007/s40261-012-0008-2

Unit costs of health and social care 2014. Kent:Personal Social Services Research Unit (PSSRU);2014.

10.1046/j.1365-2141.2003.04065.x

10.1186/1472-6963-10-209

10.1186/1472-6963-13-45

10.5402/2012/139862

10.1179/102453309X12473408860424

PepeA MeloniA RossiG et al. Direct cost analysis about the three chelators for the treatment of thalassemia patients with chronic iron overload: an Italian perspective from the MIOT Network [Internet]. Washington (DC): Blood American Society of Hematology;2013[cited 2014 Dec 2]. Available from:http://bloodjournal.hematologylibrary.org/content/122/21/5605.abstract?sid5dfe72d9a-b6f0-4354-81a6-4bf0e405ee9f\.

Fisher S, 2013, Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion‐dependent thalassaemia, Cochrane Database Syst Rev, 8, CD004450

10.3109/03630269.2013.867407

10.1186/1532-429X-16-S1-O33

10.1182/blood-2005-07-2933

Thông tin
Thông tin xuất bản

Transfusion

Tập 56 Số 5

1038-1045

Thông tin tác giả